Engineered L-Threonine Transaldolases for Broad β-OH-nsAA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing strategies for the biosynthesis of beta-hydroxy non-standard amino acids (β-OH-nsAAs) are limited by restricted substrate specificity, thermodynamic favorability, and high glycine requirements, with known L-threonine transaldolases (TTAs) facing challenges such as low affinity for L-threonine and instability of aldehyde substrates in live cell contexts.
Innovation Solution
Identification and characterization of novel L-threonine transaldolases (TTAs) with improved sequence identity, solubility tags, and expression in recombinant cells, coupled with carboxylic acid reductases to stabilize aldehydes, enabling the production of diverse β-OH-nsAAs in aerobic fermentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If threonine aldolases (TAs) are used for beta-hydroxy non-standard amino acids production, then substrate promiscuity and stereospecificity are improved, but the reaction reversibility and glycine concentration requirements worsen
Solution Approach 1:
The patent changes the chemical parameters of the reaction system by using transaldolase instead of aldolase, which fundamentally alters the reaction mechanism from reversible aldol condensation to irreversible transaldol cleavage. This parameter change eliminates the need for high glycine concentrations and prevents product decomposition, while maintaining the stereospecificity advantage.
2Reliability
If known L-threonine transaldolases (TTAs) are used, then low reversibility and high stereospecificity are achieved, but L-threonine affinity and aldehyde substrate stability worsen
Solution Approach 1:
The patent applies parameter changes by engineering specific amino acid substitutions in the TTA active site that enhance L-threonine binding affinity. The mutations modify the enzyme-substrate interaction parameters, allowing high stereospecificity to be maintained while significantly improving catalytic efficiency with L-threonine.
Solution Approach 2:
The patent uses an engineered TTA as an intermediary catalyst that stabilizes the transition state and intermediate species in the reaction pathway. This intermediary enzyme facilitates the conversion of L-threonine and aldehyde to beta-hydroxy non-standard amino acids with improved substrate binding and product stability.
3Productivity
If chemical synthesis methods are used for beta-hydroxy non-standard amino acids, then production efficiency is improved, but stereospecificity and chemical diversification capability worsen
Solution Approach 1:
The patent replaces chemical synthesis mechanisms with enzymatic catalysis. The engineered TTA provides a biocatalytic system that achieves both high production efficiency through catalysis and high stereospecificity through the chiral environment of the enzyme active site, eliminating the need for complex chiral resolution steps required in chemical synthesis.
4Manufacturing precision
If NRP synthase complexes are used for beta-hydroxy nonstandard amino acids production, then stereospecificity is improved, but substrate specificity restriction and product diversification capability worsen
Solution Approach 1:
The patent creates a universal enzymatic platform by engineering TTA with broad substrate promiscuity. The engineered enzyme can accept multiple different aldehyde substrates and L-threonine variants, enabling production of diverse beta-hydroxy non-standard amino acids with a single catalyst, thus achieving both stereospecificity and versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel TTAs exhibit higher affinity for L-threonine, broader substrate scope, and improved catalytic rates, facilitating the production of β-OH-nsAAs with bio-orthogonal conjugation handles, enhancing the potential for chemical diversification of peptides and proteins.
Implementation Method 1
L-threonine transaldolases (TTAs) can perform similar chemistry with low reversibility, high stereoselectivity, and high yields
Implementation Method 2
catalyze the aldol condensation of L-threonine (L-Thr) with an aldehyde
Implementation Method 3
coupled with carboxylic acid reductases to stabilize aldehydes
Implementation Method 4
Identification and characterization of novel L-threonine transaldolases (TTAs) with improved sequence identity, solubility tags, and expression in recombinant cells
Implementation Method 5
enabling the production of diverse β-OH-nsAAs in aerobic fermentation
Data Source
AI summary
The invention provides a method for producing in vitro a beta-hydroxy non-standard amino acid (0-OH-nsAA). The in vitro method comprises incubating L-threonine, an aldehyde and an L-threonine transaldolase (TTA). Also provided is a method for producing a beta-hydroxy non-standard amino acid (0-OH-nsAA) by recombinant cells, comprising expressing a heterologous L-threonine transaldolase (TTA) by the recombinant cells, and growing the recombinant cells in a medium. The medium comprises L-threonine and an aldehyde.